Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B-Reference-Cited by-同舟云学术

Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B

Published:2020-05-10 Issue:5 Volume:190 Page:684-695
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Rayment Rachel¹,Chalmers Elizabeth²^ORCID,Forsyth Katherine³,Gooding Richard⁴,Kelly Anne M.⁵,Shapiro Susan⁶^ORCID,Talks Kate⁷,Tunstall Oliver⁸^ORCID,Biss Tina⁷^ORCID,

Affiliation:

1. Cardiff and Vale University Health Board Cardiff UK

2. Royal Hospital for Children Glasgow UK

3. Barts Health NHS Trust London UK

4. Leicester Royal Infirmary Leicester UK

5. Cambridge University Hospitals NHS foundation Trust Cambridge UK

6. NIHR Oxford Biomedical Research Centre Oxford University Hospitals NHS Foundation Trust Oxford UK

7. The Newcastle Upon Tyne Hospitals NHS Foundation Trust Newcastle Upon Tyne UK

8. University Hospitals Bristol NHS Foundation Trust Bristol UK

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16704

Reference119 articles.

1. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A

2. Definitions in hemophilia: communication from the SSC of the ISTH

3. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

4. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)

5. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review;Blood Research;2024-08-28

2. Cost of hemophilia A in Brazil: a microcosting study;Health Economics Review;2024-08-06

3. Moving towards Normalization of haemostasis and health equity: Evolving treatment goals for haemophilia A;Haemophilia;2024-07-10

4. Which plays a more important role in hemophilia treatment, economical development or medical technology?;2024-06-10

5. Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data;Journal of Thrombosis and Haemostasis;2024-06